Pennant Investors, LP Erasca, Inc. Transaction History
Pennant Investors, LP
- $367 Million
- Q2 2024
A detailed history of Pennant Investors, LP transactions in Erasca, Inc. stock. As of the latest transaction made, Pennant Investors, LP holds 166,200 shares of ERAS stock, worth $448,740. This represents 0.11% of its overall portfolio holdings.
Number of Shares
166,200
Previous 166,200
-0.0%
Holding current value
$448,740
Previous $342,000
14.62%
% of portfolio
0.11%
Previous 0.08%
Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
133Shares Held
205MCall Options Held
3.1KPut Options Held
142K-
Vr Adviser, LLC New York, NY16.2MShares$43.8 Million4.2% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA16.2MShares$43.8 Million2.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$37.2 Million1.36% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$29.8 Million15.29% of portfolio
-
Black Rock Inc. New York, NY10.6MShares$28.7 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $330M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...